原料药制药公司BGM Group将收购Wonder Dragon，以加速“医疗保健”战略-动脉网

BGM Group Acquires Wonder Dragon to Accelerate "Healthcare" Strategy

CISION 等信源发布 2025-04-21 20:30



可切换为仅中文







CHENGDU, China

中国成都

，

April 21, 2025

2025年4月21日

/PRNewswire/ -- BGM Group Ltd. (Nasdaq:

/PRNewswire/ -- BGM集团有限公司（纳斯达克：

BGM

背景音乐

) today announced that it has signed a definitive transaction agreement with the existing shareholders of Wonder Dragon Global Limited ('Wonder Dragon'), to acquire 100% of the equity interests of Wonder Dragon by issuing 38,165,290 Class A ordinary shares at a price of

）今天宣布，已与Wonder Dragon Global Limited（“Wonder Dragon”）现有股东签署了一份最终交易协议，将以发行38,165,290股A类普通股的方式，收购Wonder Dragon 100%的股权，每股价格为

per share, for a total transaction valuation of

每股，总交易估值为

RMB550 million

人民币5.5亿元

. The transaction is expected to be completed in the second quarter of 2025.

该交易预计将于2025年第二季度完成。

Wonder Dragon possesses over 3,000 metric tons of premium Qingzhuan dark tea inventory, comprising 1,670 metric tons of raw materials and 1,350 metric tons of finished products. These premium tea products, known for their medicinal and collectible historical value, provide a solid foundation for BGM Group's research and development efforts..

奇迹龙拥有超过3000公吨的优质青砖黑茶库存，其中包括1670公吨的原材料和1350公吨的成品。这些以药用和收藏历史价值著称的优质茶产品，为BGM集团的研发工作提供了坚实的基础。

This acquisition strengthens BGM Group's position in the healthcare sector by expanding its health product portfolio and market reach. The company has been at the forefront of integrating AI technology, big data analytics, and biopharmaceutical innovations to modernize traditional industries. Post-acquisition, BGM Group plans to optimize tea production efficiency, enhance product adaptability, and accelerate the development of active ingredients for medicinal applications using its AI-powered decision-making platform..

此次收购通过扩展健康产品组合和市场覆盖，进一步巩固了北控集团在医疗保健领域的地位。该公司一直处于整合人工智能技术、大数据分析和生物医药创新以实现传统产业现代化的前沿。收购完成后，北控集团计划利用其人工智能驱动的决策平台优化茶叶生产效率、提升产品的适应性，并加速药用活性成分的开发进程。

Mr.

先生

Xin Chen

陈欣

, CEO of BGM Group, commented: 'Wonder Dragon's Qingzhuan dark tea resources, combined with our biotechnology platform, will significantly advance our medicinal tea product development and distribution. By leveraging our technological expertise, we intend to introduce new health-focused tea products like ginseng Qingzhuan dark tea and goji berry Qingzhuan dark tea, further diversifying our 'medicine + tea + health' product ecosystem.'.

BGM集团首席执行官评论道：“Wonder Dragon的青砖黑茶资源，结合我们的生物技术平台，将显著推动我们的药用茶产品开发与分销。通过利用我们的技术专长，我们计划推出新的以健康为导向的茶产品，如人参青砖黑茶和枸杞青砖黑茶，进一步丰富我们的‘医药+茶+健康’产品生态系统。”

About BGM Group Ltd

关于BGM集团有限公司

BGM Group Ltd. has a strategic focus on the technology fields of AI application, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals.

BGM集团有限公司战略布局人工智能应用、智能机器人、算力算法、云计算、生物制药等科技领域。

In terms of AI application implementation, the group relies on big data mining and AI Agent technology, and utilizes the two platforms of

在人工智能应用落地方面，集团依靠大数据挖掘和AI Agent技术，并利用两大平台

Du Xiao Bao

杜小宝

and

和

Bao Wang

包王

to provide comprehensive and professional AI solutions and intelligent robot services for insurance companies, insurance brokers, and consumers. Its services cover multiple key scenarios such as sales and marketing, underwriting assessment, claims processing, and customer service. The group is capable of analyzing consumer data, building consumer profiles, accurately predicting insurance needs, and providing highly customized services for consumers..

为保险公司、保险经纪人和消费者提供全面且专业的AI解决方案和智能机器人服务。其服务覆盖销售与营销、承保评估、理赔处理和客户服务等多个关键场景。该集团能够分析消费者数据，构建消费者画像，精准预测保险需求，并为消费者提供高度定制化的服务。

In the field of biopharmaceuticals, the group's biopharmaceutical division mainly produces oxytetracycline API, crude heparin sodium, and licorice preparations, which are widely supplied to the global animal husbandry, pharmaceutical, and drug retail markets. The group deeply integrates AI-assisted decision-making into every link of production and manufacturing, achieving supply chain optimization, process efficiency improvement, and market trend prediction.

在生物制药领域，该集团的生物制药部门主要生产土霉素原料药、粗品肝素钠和甘草制剂，广泛供应全球畜牧业、医药和药品零售市场。集团将人工智能辅助决策深度融入生产制造的各个环节，实现供应链优化、工艺效率提升以及市场趋势预测。

This provides scientific decision-making basis for the management and offers high-quality products and precise services for consumers..

这为管理提供了科学的决策依据，也为消费者提供了优质的产品和精准的服务。

For investor and media inquiries, please contact:

投资者和媒体咨询，请联系：

info@qiliancorp.com

SOURCE BGM Group Ltd

来源：BGM集团有限公司

WANT YOUR COMPANY'S NEWS

想要你公司的新闻

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？